# AstraZeneca Enhertu granted Breakthrough Therapy Designation in the US

- Link: https://www.directorstalkinterviews.com/astrazeneca-enhertu-granted-breakthrough-therapy-designation-in-the-us/412820226
- Published: 2020-05-11T07:32:23+01:00
- Author: Amilia Stone

**[AstraZeneca PLC](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
and Daiichi Sankyo Company, Limited’s _Enhertu_ (trastuzumab deruxtecan) has been
granted Breakthrough Therapy Designation (BTD) in the US for the treatment of patients
with HER2-positive unresectable or metastatic gastric or gastroesophageal junction
adenocarcinoma who have received two or more prior regimens including trastuzumab.

Gastric cancer is the third leading cause of cancer mortality with a five-year survival
rate of 5% for metastatic disease.^(1,2) Approximately one in five gastric cancers
are considered HER2 positive.^(3,4)

The Food and Drug Administration’s (FDA) BTD is designed to accelerate the development
and regulatory review of potential new medicines that are intended to treat a serious
condition and address a significant unmet medical need. The new medicine needs to
have shown encouraging early clinical results that demonstrate substantial improvement
on a clinically significant endpoint over available medicines.

> **José Baselga, Executive Vice President, R&D Oncology, said: **“Current therapy
> options are limited for patients with HER2-positive metastatic gastric cancer 
> and for those who relapse, there are no approved HER2-targeted medicines. We look
> forward to working with the FDA to further explore the potential of _Enhertu_ 
> to become an important new treatment and the first antibody drug conjugate for
> this devastating disease.”

> **Gilles Gallant, Senior Vice President, Global Head, Oncology Development, Oncology
> R&D, Daiichi Sankyo, said:** “DESTINY-Gastric01 represents the first randomised
> trial of _Enhertu_ to demonstrate clinically meaningful and statistically significant
> results, including objective response and survival increases compared to physician’s
> choice of chemotherapy. We are thrilled that the FDA has granted _Enhertu_ a second
> Breakthrough Therapy Designation.”

The FDA granted BTD based on data from the registrational Phase II DESTINY-Gastric01
trial and data from the Phase I trial published in The Lancet Oncology.^(5,6) In
DESTINY-Gastric01, patients treated with _Enhertu_, a HER2-directed antibody drug
conjugate (ADC), demonstrated a statistically significant and clinically meaningful
improvement in objective response rate (ORR), the primary endpoint, and overall 
survival (OS), a key secondary endpoint, versus patients treated with investigator’s
choice of chemotherapy (irinotecan or paclitaxel monotherapy).

The overall safety and tolerability profile of _Enhertu_ (6.4 mg/kg) in DESTINY-
Gastric01 was consistent with that seen in the Phase I trial. The most common adverse
events were haematologic and gastrointestinal including neutrophil count decrease,
anaemia, nausea and decreased appetite. There were cases of drug-related interstitial
lung disease (ILD) and pneumonitis, the majority of which were Grade 1 and 2, with
two Grade 3 and one Grade 4. No ILD-related deaths (Grade 5) occurred in patients
with gastric cancer in the Phase I trial or in the Phase II DESTINY-Gastric01 trial.

The full results of DESTINY-Gastric-01 will be presented during the 2020 American
Society of Clinical Oncology ASCO20 Virtual Scientific Program.

_Enhertu_ received SAKIGAKE designation in March 2018 by Japan’s Ministry of Health,
Labour and Welfare (MHLW) for potential use in the same HER2-positive gastric cancer
patient population and was recently submitted to the MHLW for approval. This is 
the second BTD granted for _Enhertu_ in the US. _Enhertu _received BTD in 2017 for
HER2-positive metastatic breast cancer and received approval in December 2019.

**Gastric cancer**

Gastric (stomach) cancer is the fifth most common cancer worldwide and the third
leading cause of cancer mortality; there were approximately one million new cases
reported in 2018 and 783,000 deaths.^(1) In the US, it is estimated that 27,600 
new cases of gastric cancer will be diagnosed in 2020 and more than 11,000 people
will die from the disease.^(7)

Approximately one in five gastric cancers are HER2 positive.^(2,4) HER2 is a tyrosine
kinase receptor growth-promoting protein expressed on the surface of many types 
of tumours including gastric, breast and lung cancers. Gastric cancer is usually
diagnosed in the advanced stage, but even when diagnosed in earlier stages of the
disease the survival rate remains modest.^(8) Recommended 1st-line treatment for
HER2-positive advanced or metastatic gastric cancer is combination chemotherapy 
plus trastuzumab, an anti-HER2 medicine, which has been shown to improve survival
outcomes when added to chemotherapy. For gastric cancer that progresses on 1st-line
treatment, there are no other approved HER2-targeting medicines.^(9)

**DESTINY-Gastric01**

DESTINY-Gastric01 is a registrational Phase II, open-label, multi-centre trial testing
the safety and efficacy of _Enhertu_ in a primary cohort of 188 patients from Japan
and South Korea with HER2-expressing, advanced gastric cancer or gastroesophageal
junction adenocarcinoma (defined as IHC3+ or IHC2+/ISH+) who have progressed on 
two or more prior treatment regimens including fluoropyrimidine and platinum chemotherapy
and trastuzumab. Patients were randomised 2:1 to receive _Enhertu_ or investigator’s
choice of chemotherapy (paclitaxel or irinotecan monotherapy). Patients were treated
with _Enhertu_ 6.4 mg/kg once every three weeks or chemotherapy. The primary endpoint
of the trial is ORR, as assessed by an independent review committee. Secondary endpoints
include OS, progression-free survival, duration of response, disease control rate
and time to treatment failure as well as pharmacokinetic and safety endpoints.^(
5)

**Enhertu**

_Enhertu_ (trastuzumab deruxtecan; fam-trastuzumab deruxtecan-nxki in the US) is
a HER2-directed ADC and is the lead ADC in the oncology portfolio of Daiichi Sankyo
and the most advanced programme in AstraZeneca’s ADC scientific platform. ADCs are
targeted cancer medicines that deliver cytotoxic chemotherapy (“payload”) to cancer
cells via a linker attached to a monoclonal antibody that binds to a specific target
expressed on cancer cells.

_Enhertu _is approved in the US and Japan for the treatment of adult patients with
unresectable or metastatic HER2-positive breast cancer who have received two or 
more prior anti-HER2-based regimens based on the DESTINY-Breast01 trial.

Share on:
